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CircovacIn this controlled, blinded and randomised study, Circovac, an inactivated PCV2 vaccine was used for
active immunisation of 3-week-old piglets (0.5 ml, i.m., one-shot). In a PCVD affected farm, a total of
1105 piglets from three consecutive farrowing batches were included. The vaccine efﬁcacy was assessed
by clinical parameters such as mortality, underweight pigs and improvement of average daily weight gain
(ADWG) during the fattening period. Additionally, the effect of the vaccination over time on viremia and
seroconversion was investigated in animals from the 1st and the 3rd batch. Mortality rate from start of
fattening until slaughter was reduced by 7.40% in the vaccinated group (p < 0.0001). ADWG from 13th to
21st week was improved in the vaccinated group by 64.83 g/day (p < 0.0001) and by 41.43 g/day during
the whole fattening stage. Furthermore, vaccination reduced the rate of underweight animals, especially
for the obtained weight data in the 21st week of life with 5.15% difference (p = 0.044). The percentage of
recently infected animals, characterised by being positive for IgM antibodies, as well as the detection of
speciﬁc PCV2 DNA, was reduced in the vaccinated animals and it was found concomitant with higher
mortality and underweight animals in the non-vaccinated group. From the study results it can be con-
cluded that the vaccination of piglets with Circovac reduced the viral shedding and protected the ani-
mals successfully as shown by the improvement of clinical parameters, and that it can be utilised as a
valuable instrument against PCVD.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Porcine circovirus type 2 (PCV2) is acknowledged to be the
main causative agent of different disease syndromes, which are
summarised under the speciﬁc term porcine circovirus diseases
(PCVD) [1,2]. The virus belongs to the Circoviridae family [3] and
is small (17 nm), non-enveloped and contains a closed single-
stranded circular DNA [4].
Post weaningmultisystemic wasting syndrome (PMWS)was the
earliest disease complex associated with PCV2. Although many dis-
eases havebeen linked to PCV2, PMWShas thehighest economic im-
pact on the swine industry worldwide [5,6]. Diagnosis on an
individual animal basis is conﬁrmed by 3 criteria including clinical
signs and gross lesions (i.e. wasting and/orweight loss and enlarged
lymph nodes), speciﬁc histopathologic lesions (i.e. lymphocyte
depletion associated with histiocytic giant cell inﬁltration), and
the detection of high quantities of PCV2 in affected tissues by immu-nohistochemistry (IHC) or in situhybridisation (ISH) [7,8]. Regarding
the diagnosis of PMWS on herd level, the European research consor-
tium on PCV2 proposed a deﬁnition (http://www.pcvd.net/news.
php) which included higher post weaning mortality and wasting
rates in comparison to historical farm data and a conﬁrmed diagno-
sis of PMWS in necropsied individual animals (at least one out of
ﬁve) using the abovementioned criteria. In addition to these deﬁni-
tions on diagnosing PMWS, other investigation tools have been
developed in order to achieve faster information about PCV2
dynamics within a herd. Speciﬁc ELISA tests, among which one is
detecting IgGand IgMantibodies against PCV2, havebeendeveloped
to determine the infection period [9–12]. Quantitative polymerase
chain reaction (qPCR) has been used to assess the correlation be-
tween viral DNA load in serum or tissues and the clinical disease,
whereas ISH or IHC were utilised as standards to validate the qPCR
results [13–15]. Consequently, certain thresholds for qPCR results
were proposed in order to predict the clinical outcome of a PCV2
infection according to laboratory results [13,14,16].
Improving management strategies, e.g. according to Madec’s
20-point plan [17], was the ﬁrst method to help prevent PCVDs.
2 B. Heißenberger et al. / Trials in Vaccinology 2 (2013) 1–9However, current prevention strategies against most of the PCVDs
like PMWS or PRDC include PCV2 vaccination. As previous studies
have shown, a PCV2 vaccination programme can shorten the vire-
mia period and the DNA load of PCV2 in the serum [18,19] and as a
consequence reduces the viral burden in the housing facilities.
Since 2004 Circovac (Merial, Lyon, France), an inactivated PCV2
vaccine, was available under provisional licence in some EU Mem-
ber States [20]. Following European registration in June 2007 for
gilt and sow vaccination, an approval for piglet vaccination was ob-
tained in November 2010. Recently, ﬁeld studies have established
the positive effect of vaccination in both, sows [21–23] and piglets
[21–24].
The objective of the present ﬁeld study was to better character-
ise the efﬁcacy of Circovac used for active immunisation in 3-
week-old piglets by evaluating key parameters such as average
daily weight gain (ADWG), mortality rate and rate of underweight
animals. Moreover, IgM and IgG proﬁles and viral DNA presence in
the serum of vaccinated and concomitant non-vaccinated pigs
were compared.2. Materials and methods
2.1. Study site
The selected farm was a 250-sow farrow-to-ﬁnish farm located
in Austria, which operated in a 4-week farrowing batch interval
and was originally stocked with gilts from Hermitage Germany
(Hermitage Deutschland GmbH, Golzow, Germany). All sows were
vaccinated against porcine parvovirus, Erysipelothrix rhusiopathiae,
and PRRSV, but were not vaccinated against PCV2. Piglets were
vaccinated against PRRSV and received colistinsulfat (5 mg/kg
body weight/day, Colistinsulfat 100% ‘aniMedica’, Ogris Pharma,
Wels Austria) after weaning in order to avoid colibacillosis. Prior
to the trial, the farm records showed an increased number of
underweight animals and an increased mortality rate in the nurs-
ery and the fattening period. PCV2 infection was conﬁrmed by ISH
in lymph node samples from two poor growing pigs (low- and
medium-grade positive). The histopathological examination of
their inguinal lymph nodes showed a slight lymphocyte depletion
and a giant cell inﬁltration. Additionally, using a qPCR, 3.87  105
to 3.78  106 copies of PCV2 DNA per gram of tissue were found
in lung samples from ﬁve stillborn piglets. Based on these clinical
signs and laboratory conﬁrmation, the farm was selected for this
ﬁeld study.
2.2. Vaccine
Circovac (Merial, Lyon, France), an inactivated porcine circovi-
rus type 2 vaccine, containingP2.1 log10 ELISA units per reconsti-
tuted 2 ml, was used for active immunisation of 3-week-old piglets
in the vaccinated group. Vaccinated piglets received one injection
of 0.5 ml Circovac intramuscularly in the right side of the neck
1 day before weaning, in the 3rd week of age, according to the reg-
istered recommendations. Control animals received 0.5 ml of a pla-
cebo (adjuvant-emulsion mixed with the exact same volume of
aqua bidistillata, Mayrhofer Pharmazeutika GmbH & CO KG, Leond-
ing, Austria) replacing the inactivated virus suspension.
2.3. Study design and procedures
The study design was discussed and approved by the Austrian
institutional ethics committee (allowance number: 68205/142 –
II/10b/2008). It was conducted as a randomised, blinded ﬁeld trial.
A total of 1105 piglets from three consecutive farrowing batches
were included and monitored from birth to the end of the fatteningperiod. Five hundred and forty-eight piglets (548) were allocated
to the ‘‘vaccinated group’’ and 557 piglets to the ‘‘control group’’.
Allocations to the treatment groups and selection of piglets for
blood sampling (20% per group) were done randomly via SPSS
(Version 15.0, SPSS GmbH, Munich, Germany). Additionally, the
sex of the piglets, the exact date of birth and the ear tag number
of the dams were recorded for validation of the randomisation.
Piglets from both groups stayed comingled for the entire dura-
tion of the trial in the nursery and in the fattening facilities. This
means that vaccinated and unvaccinated animals were housed to-
gether in the same pens, with direct contact. No new re-mixing did
occur up to the end of the fattening period. All animals were indi-
vidually weighed ﬁve times: at birth, at weaning: 3 weeks of age,
(also time of vaccination), at the end of the nursery period:
13 weeks of age, in the middle of the fattening period: 21 weeks
of age and at the end of the fattening period: 28 weeks of age.
Weights were used to calculate average daily weight gain (ADWG)
for each piglet which was alive at the speciﬁc time point. Under-
weight pigs were deﬁned as those having a body weight below
the average weight of the group by 25%. Mortality rates were
determined using farm records throughout nursery and fattening
periods.
During the whole study period, all animals were weekly moni-
tored by the investigator for clinical symptoms aligned with the
Clinical Propedeutics of Companion and Farm Animals [25]. The
categories for the clinical checks were body condition (very good
to bad: score 1–5), respiratory tract (regular to severe coughing:
score 1–4; dyspnoea was not registered during the study period),
faeces (pasty to diarrhoea: score 1–3), lameness (mild grade to se-
vere grade: score 1–3), skin disorders (anaemia, icterus, crusts and
petechiae: score 1–3) and ﬁnally other signs, which did not ﬁt in
the mentioned categories. Dead animals were recorded by the
farmer or the investigator with the mention of the date and a sup-
posed cause of death. Only a part of the dead animals were necrop-
sied. If the reason for death was unclear and the corpse was in a
good preservation, a necropsy was performed at the Institute of
Pathology and Forensic Veterinary Medicine of the University of
Veterinary Medicine Vienna by a professional pathologist blinded
to the study. At necropsy, samples from lung, heart, liver, spleen,
kidney, small and large intestine and inguinal lymph node were
collected and submitted to histopathological analyses. An ISH
was performed on lymph node tissues to detect PCV2 speciﬁc gen-
ome as described by Bukovsky et al. [26].
2.4. Laboratory data
Blood samples were taken from piglets from each batch by
puncture of the jugular vein. In order to assess the impact of vac-
cination on seroconversion and viremia over time, serum samples
from piglets of batch 1 (vaccinated animals: n = 20; control ani-
mals: n = 20) and batch 3 (vaccinated animals: n = 18; control ani-
mals: n = 15) were collected at 3 and 6 weeks of age and further on
every other week from 10 to 28 weeks of age. Sera were submitted
to qPCR to quantify speciﬁc PCV2 DNA and to a qualitative PCV2
speciﬁc IgG/IgM ELISA for the presence of antibodies against PCV2.
2.4.1. PCV2 viremia
An in-house qPCR for detection and quantiﬁcation of PCV2 in
blood serum was developed and performed at the Clinic for Swine
of the University of Veterinary Medicine Vienna. The High Pure PCR
Template Preparation Kit (Roche Diagnostics GmbH, Mannheim,
Germany) was used to extract DNA from 200 ll serum according
to the manufacturer’s instructions. Afterwards, the eluted DNA
was diluted 1:10 in DEPC treated, pyrogen free water (Invitrogen,
Lofer, Austria). Speciﬁc PCV2 primers and a probe were designed
to detect the replicase gene of PCV2 and to amplify a 101 base pairs
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PCR control system was established. The ntb2 system (Huber,
unpublished), consisted of a DNA fragment of Nicotiana tabacum,
with a length of 125 bp, which was cloned into a plasmid. This
plasmid was added to each qPCR reaction as a linearised plasmid
DNA. If the ntb2 system was positive, an inhibition could be ex-
cluded. Both systems, the PCV2 and the ntb2, were carried out par-
allel as duplex qPCR. Shortly, 25 ll of the PCR reaction contained
5 ll serum DNA, 1 ll plasmid DNA (ntb2 system), 0.4 lmol of for-
ward primer PCV2 (sense 50-GGT ACT CCT CAA CTG CTG TCC-30)
and 0.4 lmol reverse primer PCV2 (antisense 50-GGG AAA GGG
TGA CGA ACT GG-30), 0.2 lmol probe PCV2 (50-6FAM-ACA GAA
CAA TCC ACG GAG GAA GGG-TMR-30), 0.5 lmol forward primer
ntb2 (sense 50-ACC ACA ATG CCA GAG TGA CAAC-30), 0.5 lmol re-
verse primer ntb2 (antisense 50-TAC CTG GTC TCC AGC TTT CAG TT-
30), 0.15 lmol probe ntb2 (50-HEX CAC GCG CAT GAA GTT AGG GGA
CCA-BHQ1-30), 12.5 ml of Brilliant II QPCR Master Mix (Strata-
gene, La Jolla, USA) and 0.75 ml of DEPC treated, Pyrogen free water
(Invitrogen, Lofer, Austria). A Mx3005P QPCR Systems analyser
(Stratagene, La Jolla, USA) was used to perform the ampliﬁcation
by heating initially for 10 min at 95 C followed by 45 cycles of
15 s at 95 C and 1 min at 60 C.
In order to validate the qPCR, a comparative genome analysis of
the investigated genomic regions of PCV2 was carried out using
DNASTAR (DNASTAR Inc., Wisconsin, USA). Furthermore, similar
DNA-sequences were blasted against the GenBank sequence data-
base, which is provided by the National Center for Biotechnology
Information (NCBI) and a sufﬁcient speciﬁcity was conﬁrmed.
Speciﬁcity was checked by PCR against Swine Herpesvirus 1, Por-
cine Parvovirus, PRRSV and Lawsonia intracellularis. Sensitivity
was determined using a plasmid DNA dilution series of 109–102
in triplicates and the limit of detection was identiﬁed at 10 cop-
ies/ml.2.4.2. Serological analysis
Detection of PCV2 speciﬁc IgG and IgM was performed using a
commercial ELISA (Ingezim Circovirus IgG/IgM, (Inmunología y
Genética Aplicada, S.A., Madrid, Spain) according to the manufac-
turer’s speciﬁcations. The ELISA reader 680 (Bio-Rad, Vienna,
Austria) was used to measure the optical density (OD) of the
samples at a wavelength of 450 nm and the Microplate Manager
software (Version 5.2.1, Bio-Rad, Vienna, Austria) was applied for
processing the obtained results. The infection period has been
determined as follows: high PCV2 IgM antibody values with no
or low IgG titre values indicate that sampling was made within
21 days post infectionem (DPI). Higher IgG antibody titres with
lower IgM values indicate that sampling was made between 20
and 50 DPI and if there are only high PCV2 speciﬁc IgG titre values,
sampling was made at least 60 DPI [9].2.5. Presentation of laboratory results
The qPCR results were presented in arithmetic mean values,
which were log-transformed. Additionally, a threshold at 106 cop-
ies of viral DNA/ml serum has been chosen to discriminate data, as
this threshold had been correlated with clinical signs of PMWS af-
fected pigs in previous reports [18,19,27]. Furthermore, the area
under the curve (AUC) has been calculated for each batch. The
Ingezim ELISA is a qualitative, PCV2 speciﬁc IgG or IgM assay.
Therefore, results were presented as percentage of positive animals
for IgG or IgM antibodies at each time point. Furthermore, a com-
bination of the results for IgG and IgM antibodies allows to hypoth-
esise a dating of the PCV2 infection period as described above
[9,23].2.6. Data evaluation and statistical analysis
The individual piglet was the statistical unit and the signiﬁ-
cance level was set at p = 0.05. Figures were created with Mirco-
soft Excel 2003 and for further statistical analysis the SPSS 15.0
(SPSS GmbH, Munich, Germany) software was used. According to
the ADWG, mean values were compared between the two study
groups using an Analysis of Covariance (ANCOVA) with the dam
and the batch number as co-factors. The mean qPCR values were
compared with a General Linear Model (GLM) Repeated Measure-
ment (RM) including the dam and the batch number of the piglets
as co-factors. Concerning the AUC, a GLM RM has been used to as-
sess differences for the whole model for batch 1 and 3 respectively.
Afterwards, a one-way ANOVA has been calculated for each batch
to identify signiﬁcant differences between the two groups at the
speciﬁc time points. The number of underweight pigs, the mortal-
ity rate and the data of the clinical examination were analysed
using a v2 test, in order to rate signiﬁcant differences between
the two study groups. The serological results and the obtained
thresholds based on the qPCR results were analysed using a non-
parametric Mann–Whitney test.3. Results
3.1. Average daily weight gain and growth performance (ADWG)
From the 1105 pigs included in this trial, 548 piglets were allo-
cated to the vaccinated and 557 piglets to the control group. No
statistically signiﬁcant differences regarding distribution of sex
and weight were observed at the start of the study, nor at the vac-
cination time point (weaning); however, there was a sow effect at
birth, but this effect did not exist anymore at weaning. Concerning
the batch as co-factor for the weight, there was no signiﬁcant dif-
ference between the vaccinated and the control group, except at
13 weeks of age (end of the nursery period). At this time point,
all animals in batch 1 had a higher level in ADWG as pigs in batch
2 and 3, but there was no signiﬁcant difference between the vacci-
nated and the control group within the batches.
Mean ADWG were displayed as gram per day (g/day) and in-
cluded the results of all animals from all three batches. Table 1
shows the mean ADWG for the speciﬁed time periods, standard
deviation, difference between the study groups and p-values. In
the nursery, 3–13 weeks of age, no signiﬁcant difference was ob-
served between the two groups (p = 0.9095). The most apparent
signiﬁcant difference in ADWG in favour of the vaccinated animals
was 64.83 g/day (p < 0.0001) between week 13 and 21. Between
week 21 and 28, vaccinated animals gained 15.66 g/day more than
pigs in the control group (p = 0.1523). Vaccinated pigs performed
signiﬁcantly better than non-vaccinated ones during the whole fat-
tening period (41.43 g/day from 13 to 28 weeks of age, p < 0.0001).
3.2. Underweight animals
The percentage of underweight animals from each group was
calculated for each speciﬁc time point as shown in Table 2. For
the nursery period, no signiﬁcant difference was observed between
the two groups. A signiﬁcant difference was detected for the body
weights at week 21 with 5.15% more underweight pigs in the con-
trol group (p = 0.044). At the end of the study, the difference re-
mained at 2.09%.
3.3. Mortality
Mortality rates were calculated for two time intervals:
13–21 weeks of age and 21–28 weeks of age, as well as for the
Table 1
Average daily weight gain (g/day and standard deviation) during the different study periods.
Daily weight gain (g/day) Age (in weeks) Vaccinated groupa Control groupb Differencec p-value
Nursery 3–13 294.85 (±85.51) 294.21 (±90.48) 0.64 0.9095
First period of fattening 13–21 584.80 (±159.35) 519.97 (±188.40) 64.83 <0.0001
Second period of fattening 21–28 723.12 (±152.67) 707.46 (±171.43) 15.66 0.1523
Fattening period 13–28 651.04 (±123.57) 609.61 (±139.07) 41.43 <0.0001
Nursery and Fattening period 3–28 509.06 (±91.05) 484.54 (±99.77) 24.52 0.0001
a n = 474, 462, 451, 451, 451 animals for 3–13, 13–21, 21–28, 13–28, 3–28 weeks of age.
b n = 491, 448, 429, 429, 429 animals for 3–13, 13–21, 21–28, 13–28, 3–28 weeks of age.
c Difference between pigs in the vaccinated group and the control group in g/day.
Table 2
Percentage of underweight animals at each weighing time point.
Underweight
animals
Vaccinated group
(%)
Control group
(%)
Difference
(%)
13th week 18.53 17.52 1.01
21st week 14.72 19.87 5.15*
28th week 8.87 10.96 2.09
* Signiﬁcant difference: p = 0.044.
Table 3
ISH data of necropsied study animals.
PCV2 detection via
ISH
Vaccinated groupa
(%)
Control groupa
(%)
Difference in
%
Investigated
animals
17 22
Positive +b 2 (11.76%) 4 (18.18%) 6.42%
Positive ++c 1 (5.88%) 5 (22.73%) 16.85%
Positive +++d 1 (5.88%) 2 (9.09%) 3.21%
aNumber (percentage) of animals per group.
b,c,dClassiﬁcation according to ISH from mild (+), to moderate (++) and severe (+++).
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oratory results (PCR and serology), the ﬁrst interval (13th–21st
week) corresponded to the period, when most of the investigated
animals were positive for PCV2 DNA. During this period, mortality
rates were 2.53% in the vaccinated group as compared to 8.55% in
the control group (p < 0.0001). In the second part of the fattening
period (21–28 weeks of age), mortality rates were 1.52% in the
vaccinated group and 3.12% in the control group (p = 0.1247).
During the whole fattening period (13–28 weeks of age), 4.01%
of the vaccinated pigs and 11.41% of the control animals died,
which resulted in a signiﬁcant difference of 7.40% in mortality
rates (p < 0.0001).
3.4. Necropsy evaluation
Necropsy and further diagnostics such as histopathology and
ISH for PCV2 DNA in tissues from the inguinal lymph node were
performed on dead animals with unknown reason of death. De-
tailed numbers are shown in Table 3. In total, 17 animals of the
vaccinated group and 22 animals of the control group were exam-
ined and PCV2 was detected by ISH in necropsied animals from
15 week of age till week 26. According to the number of positive
signals found by ISH, the infection was classiﬁed from mild to se-
vere. The largest difference was seen in the class with ‘‘moderate
infection’’ with 16.85% more non-vaccinated pigs classiﬁed ++ po-
sitive than vaccinated pigs (week 16 until week 22), while the per-
centage of animals with severe infection was in general lower in
both groups (5.88% in the vaccinated and 9.09% in the control
group).
3.5. Evaluation of the clinical examination
Most frequently, observations of clinical signs were noted in the
category ‘‘body condition’’ (33.1%), followed by ‘‘skin disorders’’
(19.7%) and to the same degree ‘‘faeces’’ (13.7%) and ‘‘lameness’’
(13.4%). No signiﬁcant differences were found between the two
experimental groups.
3.6. PCV2 viremia
Fig. 1 shows the mean logarithmic values of copies of viral
DNA per ml serum in batch 1 and 3 at each investigated time
point for the vaccinated and the control group. In batch 1, ani-mals from both groups had detectable amounts of speciﬁc PCV2
DNA at 6 weeks of age; the control group started at a higher level.
A rise in the quantity of PCV2 DNA was detected from week 14
onwards, with a peak close to 106 DNA copies/ml at 16 weeks
of age in the control group followed by a sharp decrease after
week 24. The vaccinated group followed more or less the course
of the control group at a signiﬁcantly lower level (approximately
103 DNA copies lower at the peak). A signiﬁcantly lower amount
of PCV2 DNA was found in sera from vaccinated pigs at week 10
and from week 14 to 24. In batch 3, no PCV2 DNA was detected at
6 weeks of age in any group; the peak in the control group ap-
peared in weeks 14–16 (approximately 104 DNA copies). As in
batch 1, the vaccinated group had lower values compared to
the control group (approximately 102 DNA copies lower at the
peak). A signiﬁcant difference was found at 18 weeks of age. All
in all, batch 3 showed a similar course of PCV2 viremia, but the
values appeared constantly lower than those of batch 1. Further-
more, the decrease of the amount of PCV2 DNA in the serum was
faster in batch 3. Fig. 2 shows the percentage of vaccinated and
control animals exceeding 106 copies of PCV2 DNA per ml serum
in batch 1 and 3. The percentage of animals, which had high
amounts of PCV2 DNA in serum, was signiﬁcantly higher in the
control group of the ﬁrst batch at 14 and 16 weeks of age com-
pared to the vaccinated group. In batch 3, a numeric but not sig-
niﬁcant difference was seen between the vaccinated and the
control group from week 14 to 20. Furthermore, the percentage
of animals exceeding the threshold was lower for the entire batch
3 in comparison to batch 1. Fig. 3 shows the PCV2 DNA AUC for
batch 1 and 3 in comparison. Regarding the GLM RM for batch
1, there was a statistically signiﬁcant difference between the vac-
cinated and the control group (p < 0.0000). The one-way ANOVA
revealed that this difference was statistically signiﬁcant at all
time points, except week 6 and 12. Concerning the whole model
of the AUC from batch 3, a numeric difference close to the signif-
icance level was found (p = 0.0526). In detail the AUC for batch 3
was lower from week 18 on and this difference became statisti-
cally signiﬁcant in weeks 24 and 26. Similar as described in
Fig. 1, the values of both experimental groups in batch 3 appeared
lower than those of batch 1. When combined in the GLM RM, the
two batches showed a statistically signiﬁcant difference in the
AUC: p = 0.0007.
week of life 10th week 14th week 16th week 18th week 20th week 22nd week 24th week
p – values 1st batch 0.0037 0.0030 0.0004 0.0000 0.0154 0.0000 0.0483 
p – values 3rd batch - - - 0.0362 - - - 
*
* * *
*
* *
*
Fig. 1. Logarithmic mean values of PCV2 qPCR results from animals of the 1st and the 3rd batch. ⁄Signiﬁcant differences between the groups (p < 0.05).
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Fig. 2. Percentage of animals from the vaccinated and the control group exceeding the threshold of 106 copies of PCV2 DNA /ml serum from the 1st and the 3rd batch at the
investigated time points. Signiﬁcant differences between the groups in the 1st batch () were obtained in the 14th (p = 0.0004) and the 16th week of life (p = 0.0002). No
signiﬁcant differences were obtained in the 3rd batch.
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Fig. 4a and b show the percentage of sera positive for PCV2 IgG
in vaccinated and control animals in batch 1 and 3. In batch 1, pigs
positive for IgG antibodies at 3 weeks of age were 75% in the vac-
cinated group and 45% in the control group, respectively. From 6 to
12 weeks of age, those percentages decreased gradually in both
groups, reaching 10% for the vaccinated and 5% for the control
group. At week 14, the percentage of seropositive animals rose to
25% in the control group and to 15% in the vaccinated group. From
week 16 until the end of the study, the percentages constantly
remained P80% in both groups. Fig. 4b shows a different course
for IgG antibodies in batch 3. At 3 weeks of age, 66.67% of the
non-vaccinated pigs and 35.29% of the vaccinated pigs were
positive, whereas from week 6 until week 12, no control group
animal was positive for IgG antibodies. In the vaccinated group,
the percentage of positive pigs declined to 5.56% at 6 weeks of
age and increased up to 100% at 18 weeks of age. At week 14,
33.33% of the pigs in the control group of batch 3 were positive;
from week 16 onwards, both groups showed similar percentages
of IgG antibody positive animals.
Fig. 5a and b show the course of PCV2 speciﬁc IgM antibodies.
No pigs were positive for IgM antibodies at 3 weeks of age in any
group from any batch. In batch 1 (Fig. 4a), 15% of the vaccinatedanimals were positive at 6 weeks of age. Pigs from the control
group were positive between week 10 and 24, with a peak of
80% positive pigs at week 16. In the vaccinated group, positive ani-
mals were found from 14 to 20 weeks of age, showing a peak of
45% seropositive animals in week 16 as well. Signiﬁcant differences
between the experimental groups of the ﬁrst batch were found at
14 (p = 0.0012) and 16 weeks of age (p = 0.0225). Similar to batch 1,
vaccinated animals of batch 3 were positive for IgM antibodies at
week 6 and from week 14 to 18. Pigs from the control group in
batch 3 were found to be IgM positive from the week 14 to 18.4. Discussion
Since its introduction to control PCVD in the offspring of vacci-
nated sows, several studies have demonstrated the beneﬁcial effect
of Circovac [20,22–24]. Since November 2010, its application
range has expanded to the active immunisation of piglets. This
study provides further information about the efﬁcacy of Circovac
in piglets, based on the results obtained by investigating deﬁned
key parameters like ADWG, mortality rate, or laboratory results.
The vaccination proved its positive economic effect by signiﬁ-
cantly improving the ADWG during the main viremia period and
the overall fattening period. During the nursery period, a difference
week of life 10th week 14th week 16th week 18th week 20th week 22nd week 24th week 26th week 28th week
p –  values 1st  batch 0.0232 0.0036 0.0121 0.0004 0.0021 0.0000 0.0001 0.0000 0.0000
p – values 3rd batch - - - - - - 0.0264 0.0433 - 
*
*
* *
* *
* *
*
*
*
Fig. 3. Area under the curve (AUC) for batch 1 and 3. : Signiﬁcant differences between groups (p < 0.05).
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Fig. 4. (a and b) Percentage of animals positive for PCV2 speciﬁc IgG antibodies compared between the vaccinated and the control group of batch 1 (a) and batch 3 (b).
Signiﬁcant differences in batch 1: week 22: p = 0.037, week 26: p = 0.037. Signiﬁcant differences in batch 3: week 12: p = 0.029.
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Fig. 5. (a and b) Percentage of animals positive for PCV2 speciﬁc IgM antibodies compared between the vaccinated and the control group of batch 1 (a) and batch 3 (b).
Signiﬁcant differences in batch 1: week 14: p = 0.004, week 16: p = 0.024.
6 B. Heißenberger et al. / Trials in Vaccinology 2 (2013) 1–9of only 0.64 g/day in ADWG occurred between the two groups. This
indicates that the vaccination did not have any negative inﬂuence
on weight gain during this period and was well tolerated. In accor-
dance with Fachinger et al. and Kixmöller et al. [18,19], the mostprominent difference in weight gain in our study (64.83 g/day in
the vaccinated group) took place during the main viremia period,
when PCV2 developed its greatest inﬂuence. In addition, the most
signiﬁcant reduction in the rate of underweight animals occurred
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fact that unvaccinated animals were more susceptible to the im-
pact of a PCV2 infection [28].
Another important parameter in evaluating the vaccine efﬁcacy
is the mortality rate [29,30]. Similar to other studies [18,19,31], no
difference in the pre-viremia mortality was found. There are sev-
eral reports of a higher mortality rate in non-vaccinated animals
after the onset of viremia [18,19,31]. Segalés et al. investigated
the ability of a PCV2 vaccine to reduce PMWS associated mortality
in a ﬁeld trial [29]; differences in post weaning mortality between
the vaccinated and the control group ranged from 4.13% to 12.79%.
In the present study, a signiﬁcant difference of 7.40% in mortality
rate was observed between the vaccinated and the control group
over the whole fattening period (week 13–28 of age).
In order to evaluate the impact of the vaccination on viremia
and seroconversion over time and to stay within the ﬁnancial
framework of the study, animals from the 1st and the 3rd batch
were selected for laboratory investigation. According to the qPCR
results, the main viremia occurred between the 14th and 22nd
week of age in the 1st batch and between the 14th and 18th week
of age in the 3rd batch. In general, the values of the vaccinated
animals were consistently lower than those of the control group
(102–103 DNA copies). Similar reduction proportions were shown
by Fraile et al. or Cline et al. [24,32]. As it was shown for other
PCV2 piglet vaccines [18,27,29,33], the vaccine investigated in this
study was able to signiﬁcantly reduce the viremia in vaccinated
animals. As it was shown by Horlen et al., the reduction of viral
shedding on a herd level is important in order to reduce the
‘‘pig-to-pig viral transmission’’ [31]. Fort et al., proved that PCV2
shedding was reduced in PCV2 vaccinated animals by analysing
nasal and faecal swabs via qPCR [33,34]. Fraile et al. investigated
the reduction of the viral load in serum and the reduction of virus
excretion through faeces in a ﬁeld trial with the same vaccine used
in this trial [24]. Therefore, the vaccination provides not only pro-
tection for the individual animal, but also decreases the chance of
horizontal transmission of the virus within the vaccinated herd.
Certain animals of the control group of the 1st batch had detectable
amounts of PCV2 DNA in the 6th week of age, where we can only
assume that single animals had an early infection after weaning
and were not only immune-compromised, but also shed the virus
to their pen mates. In the same period, no control animals were
found to be positive for IgM antibodies, whereas certain animals
of the vaccinated group were IgM positive. One possible explana-
tion for this scenario would be that vaccinated animals showed a
response to the vaccination in the 3rd week of age and that the
few infected control animals would have shown an IgM response
to the natural infection in week 8. However, no differences in
ADWG were observed between the groups in this period and, as
Figs. 1–5 show, the broad mass of pigs experienced the infection
later, at the end of the nursery period and the beginning of the
growing period respectively.
According to Kixmöller et al. and Martelli et al., a threshold of
106 copies of viral DNA/ml serum has been chosen for presenting
the qPCR data, as this threshold has been postulated to be clinically
relevant for the development of PMWS [19,27]. Other authors sug-
gested a threshold of 107 copies of viral DNA/ml of serum to dis-
criminate between clinical and sub-clinical PMWS [13,14];
however, results obtained by different PCR techniques in different
laboratories should be compared carefully, as stated by Harding
et al. and Hjulsager et al. [35,36]. Furthermore, this deduction
was drawn from investigations conducted in non-vaccinated herds,
without including any factors of reducing the viral burden after
vaccination in the facilities.
Serological analyses were performed in order to gain more in-
sight into seroconversion and to estimate the infection period in
this study. Assuming that seroconversion takes place approxi-mately 2 weeks after PCV2 infection [37–39], the infection period
took place at the end of the nursery and/or the very beginning of
the growing period. According to several reports (Grau-Roma
et al. and other authors [33,38,40,41]), the optimal time of vaccina-
tion should be after maternally derived antibodies (MDA) have
waned, in order to avoid any interference with the vaccination,
and before pigs face the natural infection with PCV2. Regarding
the labour perspective, farmers are more likely to accept another
handling of the piglets at weaning rather than in later stages of
the nursery. To investigate the possible inﬂuence of MDA and the
time point of vaccination, Fachinger et al. classiﬁed all study ani-
mals vaccinated with a sub-unit vaccine in groups of high or low
MDA antibody titres at the time of vaccination; vaccinated ‘‘high
titres’’ animals had similar ADWG compared to vaccinated ‘‘low ti-
tres’’ animals [18]. Opriessnig et al. [41] found no negative inﬂu-
ence of MDA on a piglet vaccination with a killed PCV 1–2
chimeric vaccine. Fort et al. investigating a different sub-unit vac-
cine described a ‘‘slight interference’’ with maternal immunity in
vaccinated piglets, but the vaccine was able to induce an antibody
production after vaccination [33]. In a different study investigating
the same vaccine, Fort et al. observed a negative effect of high MDA
on active seroconversion after vaccination, while no inﬂuence oc-
curred on the vaccine efﬁcacy in general [38]. Fraile et al. investi-
gated a possible inﬂuence of MDA and an interference with the
humoral response towards the vaccination with the same product
used in this study [24]. This group found a signiﬁcant negative cor-
relation between high MDAs and the increase of PCV2 antibody ti-
tres after vaccination. Based on this data, they established a cut-off
value for maternal antibody interference; however, no negative
inﬂuence on production parameters, like ADWG and mortality rate
e.g., could be observed [24]. According to those ﬁndings, there
might be a potential explanation for the different serologic pictures
of batch 1 and 3 in regards to IgG antibodies. A higher percentage
of vaccinated animals with MDA at vaccination in the 3rd week of
age was found in batch 1 (75%) than in batch 3 (35.29%). Hence, we
saw no humoral reaction 3 weeks after vaccination in the 1st batch
and the IgG antibody pattern looked more or less similar to those
of the control animals. Concerning batch 3, there was a humoral re-
sponse 3 weeks after vaccination and in the following weeks. How-
ever, vaccinated animals performed better compared to the control
animals in terms of production parameters or viremia reduction no
matter if they had a detectable humoral immune response after
vaccination or not. This highlights the importance of the cellular
immune response, as emphasised by other authors before
[24,42,43]. Nevertheless, the ideal period for vaccination would
have been after the 6th and before the 10th week of age in our
study, in order to avoid any interference with MDA and to vacci-
nate before the majority of the animals would have been exposed
to PCV2. In agreement with the before mentioned studies and in
combination with our achieved results, namely the signiﬁcant
reduction of viremia and mortality, and the signiﬁcant improve-
ment of ADWG, we conclude in concordance with Fraile et al. that
the inactivated whole virus vaccine worked well in the face of MDA
[24].
The ELISA investigations moreover showed that results can vary
between different batches and that serologic results should
generally be interpreted with care. Other studies described sero-
conversion proﬁles in one herd [18,27,44,45] or in different herds
[46–50], but none of these studies investigated different batches
within one herd. In batch 1, a high percentage of vaccinated pigs,
started with MDA in contrast to batch 3, although pigs were
randomly allocated at birth to their treatment groups and stayed
commingled in the pens. Thus, it would not be possible to distin-
guish vaccinated from control group pigs according to the IgG anti-
body proﬁle in batch 1 in contrast to batch 3. Depending on the
technique used, ELISA responses cannot be linked with protection.
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to the vaccine and the reduction of viremia or the improvement
of the ADWG [51]. Moreover, Fenaux et al. underlined that vacci-
nated piglets were even protected in the absence of an active ELISA
seroconversion after vaccination [52]. Therefore, serologic results,
especially qualitative results as obtained in our study, have to be
combined with other results like qPCR data, clinical data or ADWG
measurements in order to be a useful tool to interpret vaccine efﬁ-
cacy under ﬁeld conditions. A better way to predict protection of
vaccinated animals might have been the measurement of PCV2
neutralising antibodies, since they seem to correlate with protec-
tion against PCV2 [53]. However, serum-virus neutralisation assays
are difﬁcult to perform and not easy to implement as a routine
diagnostic tool [54].
In summary, vaccination showed a positive effect in this partic-
ular farm by signiﬁcantly reducing PCV2 viremia, signiﬁcantly
increasing average daily weight gain during the study period, and
signiﬁcantly reducing mortality rate and the percentage of under-
weight animals during the main viremia period. These ﬁeld trial re-
sults conﬁrm that vaccination of piglets with 0.5 ml Circovac as
one-shot was a useful tool against the detrimental health and
economic effects of PCV2 in a farm heavily impacted with PCVD.
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